The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC).
 
Przemyslaw Twardowski
Stock and Other Ownership Interests - Exelixis
Consulting or Advisory Role - Algeta ASA; Dendreon; Janssen Biotech; Medivation/Astellas; Sanofi
Speakers' Bureau - Algeta/Bayer; Dendreon; Janssen Biotech; Medivation/Astellas; Sanofi
Research Funding - Dendreon
 
Melissa Plets
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genentech; GlaxoSmithKline; Merck; Novartis
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending (Inst)
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - Exelixis; Medivation; Takeda
 
Catherine M. Tangen
No Relationships to Disclose
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Janssen Biotech
Speakers' Bureau - Bayer; Caris MPI; Dendreon; GlaxoSmithKline; Medivation; Millennium; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Ian Murchie Thompson
Honoraria - Baptist Health Care system; Knapp Healthcare
Consulting or Advisory Role - Exosome diagnostics; Magforce; OncocellMDX
Patents, Royalties, Other Intellectual Property - I have been involved in the establishment of a new company - NanoTX Therapeutics to commercialize a novel therapy for glioblastoma for our cancer center. I am on the Board of Directors and it has intellectual property developed by our cancer center.; I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comm
Travel, Accommodations, Expenses - OncoCellMDx
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Astex Pharmaceuticals; Clovis Oncology; Exelixis; Halozyme; Immunogen; Janssen; Lilly; LPath; Medivation; Novartis; Pfizer; Sanofi; Teva; US Diagnostic Services
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Janssen Biotech (Inst); Millennium (Inst); Oncogenex (Inst); Polaris (Inst)